Michel de Baar

Michel de Baar, PhD, MBA is an accomplished business development and licensing professional currently serving as the Executive Director of BD&L for Infectious Diseases & Vaccines, CardioMetabolic- and Immunology Diseases at MSD (Merck & Co. Inc).1

In his current role at MSD, which he has held since September 2016, Michel leads the search and evaluation for early-stage business development and licensing opportunities in Europe and the Middle East. His focus areas include Infectious Diseases & Vaccines, Respiratory and Immunological indications, and Cardiovascular & Metabolic Diseases.1

Michel's career is characterized by his ability to bridge science and business. He has extensive experience in all aspects of business transaction processes within the global pharmaceutical, biotechnology, and diagnostics industries.1

Prior to joining MSD, Michel co-founded and served as the Chief Business Officer of Madam Therapeutics from 2011 to 2016. This biotech company focused on developing topical products based on antimicrobial peptides for infectious diseases and immunology.1

Michel's educational background includes:

• A PhD in Medicine from the University of Amsterdam (1996-2000)
• An MSc in Medical Biology/Biomedical Sciences from Universiteit Utrecht (1991-1995)
• An Executive MBA from Rotterdam School of Management, Erasmus University (2009-2010)1

Throughout his career, Michel has demonstrated expertise in various areas, including in-licensing, mergers and acquisitions, out-licensing, partnerships, complex negotiations, product development, and alliance management.1 He is also a member of the Licensing Executives Society (LES).1

Michel is known for his active engagement in the pharmaceutical and biotechnology community, often participating in workshops and events related to drug discovery and business development.23